Enveric Biosciences Reports Continued Losses on Both Windows of Its Quarterly Form Filing, With Going-Concern Doubt Flagged

Bottom line

Enveric Biosciences, Inc. (ENVB) remains a clinical-stage biotechnology issuer whose reported results for the three months ended June 30, 2026 and the six months ended June 30, 2026 continue to show losses on both the top of the income statement and on a per-share basis, with no reported revenue and an accumulated deficit carried forward since inception. Management explicitly states that the company's cash on hand is not sufficient to satisfy operating cash needs for the months following this filing and that substantial doubt exists about the ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements. The filing is identified as 10-Q covering the fiscal period period-ended-2026-06-30, filed under accession 0001493152-26-038418 for CIK 0000890821, and the source scope for this analysis is limited strictly to that filing and its referenced exhibits.

- For the three months ended June 30, 2026, the company reported Operating Income (Loss) of -$3,027,441, compared with -$2,519,049 in the prior-year quarter — both losses, with the current quarter authorized as a decrease against the prior-year quarter; the same quarter posted Net Income (Loss) Attributable to Parent of -$3,027,733 versus -$2,519,181, also a loss in both periods and authorized as a decrease year over year. The diluted loss per share for the quarter was -$0.76 per diluted share versus -$11.65 per diluted share, an authorized increase within a loss-to-loss transition.

- For the six months ended June 30, 2026, Operating Income (Loss) was -$4,660,611 against -$4,706,582, Net Income (Loss) Attributable to Parent was -$4,661,206 against -$4,704,147, and the diluted loss per share was -$1.7 per diluted share against -$25.76 per diluted share — all three comparisons sit inside loss-to-loss transitions, with operating loss, net loss, and per-share loss each authorized as an increase (i.e., a smaller loss) on a year-over-year basis at the half-year window.

- The source scope here is restricted to the unaudited condensed consolidated financial statements and the narrative disclosures in Item 5, Item 4, Item 1, Item 1A, Item 6, Item 3, and Item 2, together with the explanatory notes referenced by Note 9, Note 10, and Note 2. No other filings, press releases, market data, or third-party research have been used.

- The filing evidence does not disclose segment-level revenue or expense detail for the operating loss lines reported above. The filing evidence contains no peer or industry comparison against which to benchmark the per-share or net-loss results. The filing evidence does not attribute this change to any single cause. Readers looking for cross-issuer context can compare the loss-persistence framing in Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction, which covers a similarly structured clinical-stage loss profile in the same reporting window.

Financial performance

Enveric Biosciences, Inc. filed its 10-Q under accession 0001493152-26-038418 (CIK 0000890821, ticker ENVB) covering the three-month period the three months ended June 30, 2026 and the six-month period the six months ended June 30, 2026, with prior-year comparatives shown for the three months ended June 30, 2025 and the six months ended June 30, 2025. The reported bottom-line results sit on the loss side of the ledger across both windows.

For the three-month window, Net Income (Loss) Attributable to Parent was -$3,027,733 USD, compared with a prior-year loss of -$2,519,181 USD; the authorized direction for that comparison is a year-over-year decrease in the loss. Operating Income (Loss) for the quarter was -$3,027,441 USD, against a prior-year loss of -$2,519,049 USD, with the authorized direction again being a year-over-year decrease in the loss. Earnings Per Share, Diluted for the quarter was -$0.76 per diluted share USD/SHARES, against -$11.65 per diluted share USD/SHARES in the prior-year quarter, with an authorized loss-to-loss transition and an authorized increase in the per-share figure.

For the six-month year-to-date window, Net Income (Loss) Attributable to Parent was -$4,661,206 USD, compared with a prior-year loss of -$4,704,147 USD, with the authorized direction being a year-over-year increase (a smaller loss). Operating Income (Loss) for the six-month period was -$4,660,611 USD, against -$4,706,582 USD in the prior year, again authorized as a year-over-year increase from loss to loss. Earnings Per Share, Diluted for the six-month period was -$1.7 per diluted share USD/SHARES, against -$25.76 per diluted share USD/SHARES in the prior-year comparable, with an authorized loss-to-loss transition and an authorized increase in the per-share figure.

The three-month and six-month losses are consistent with management's going-concern narrative in Item 1A, which states that the company has incurred losses since inception, has not yet generated revenue as a research and development company, and has funded operations principally through equity issuance. Management describes existing cash resources as sufficient only for a limited period and explicitly flags substantial doubt about the ability to continue as a going concern for one year from issuance of the unaudited condensed consolidated financial statements; this framing should be read alongside Note 2, which is referenced as the location of the company's significant accounting policies. The filing evidence does not attribute this change to any single cause.

On accounting context, the filing notes a Reverse Stock Split retroactively reflected in prior share and per-share figures, with fractional shares rounded up. Management states that there were no significant changes to the company's significant accounting policies during the three and six months ended June, and that operating results are not necessarily indicative of full-year results. Note 9 and Note 10 address mezzanine equity and the exclusion of potentially dilutive securities from diluted per-share calculations, which is the basis for the diluted EPS figures above.

The filing evidence contains no peer or industry comparison.

The filing evidence does not disclose segment-level detail for this dimension.

Management has not provided forward guidance in a quantitative form within this filing, so expected near-term performance is best framed around the stated liquidity position and the going-concern paragraph rather than around explicit forecasts. Readers comparing this small-cap clinical-stage profile to peers can place it next to similar loss-persistent filings such as the Lizely Finance Earnings Analysis — Veru Inc. interim filing and the REINSURANCE GROUP OF AMERICA INC period-ended filing for directional context, noting that the latter is a profitability-oriented counterpoint rather than a like-for-like peer.

Operating drivers and segments

The company operates as a single segment, with consolidated loss from operations serving as the measure of segment profit or loss regularly reviewed by the chief operating decision maker. The cited note confirms that total assets, as reported on the balance sheet, function as the measure of segment assets. The filing notes there are no significant segment expenses beyond what is already included in consolidated loss from operations, namely general and administrative and research and development spend. Reported operating loss for the three-month reporting period sits at -$3,027,441 USD, while the prior-year three-month comparative stands at -$2,519,049 USD. On a six-month year-to-date basis, operating loss is -$4,660,611 USD against a prior-year comparative of -$4,706,582 USD. Because only one operating segment exists, segment-level margin trends cannot be decomposed beyond the consolidated figures shown, and no internal divisional breakdown is offered in the evidence available.

Management describes Enveric as a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics targeting psychiatric and neurological disorders, with its lead candidate positioned to engage dual receptor targets for fast-acting antidepressant and anxiolytic effects. The lead asset has been advanced into formal preclinical development studies in support of a future Investigational New Drug filing. Management explains that a prior program series was out-licensed in the fourth quarter of a recent period to a third party in exchange for development and milestone payments, and that a new non-hallucinogenic series was unveiled earlier in the year to broaden the pipeline. The filing also discloses a reverse stock split effected during the period, with all prior share and per-share information retroactively adjusted. Management further states that the company has incurred losses since inception, has not yet generated revenue, and has operating cash outflows for the six months covered by the report. Existing cash resources are expected to fund operations only for a limited period, and management anticipates the need for additional capital through public or private equity or debt financings, collaborations, or disciplined cash spending. Should capital not be raised, management indicates that further cost-cutting measures, including delaying or discontinuing certain operating activities, may be required.

The going-concern framing dominates management's discussion of liquidity, and the filing explicitly raises substantial doubt about the ability to continue as a going concern for a period of one year from issuance of the financial statements. The company's own characterization of expenses is limited to general and administrative and research and development categories, with no revenue line to offset. Year-over-year direction at the operating-loss line is authorized for both windows: the six-month year-to-date period shows an increase compared with the prior-year comparative, while the three-month reporting period shows a decrease compared with the prior-year comparative, with both periods remaining in a loss-to-loss transition. The evidence does not connect those moves to any single cost driver, The filing evidence does not attribute this change to any single cause.. No peer or industry benchmark is provided, The filing evidence contains no peer or industry comparison.. A reader looking for comparable clinical-stage biotech operating-loss patterns can cross-check against filings such as REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing or Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction, though those references sit outside the filing evidence and do not constitute peer comparison for this company.

Cash flow and capital

- Reported facts The condensed consolidated balance sheet at the balance sheet date of June 30, 2026 shows two working-capital liability lines. Accounts Payable, Current stood at $682,794 (per the cited note) and the broader Accounts Payable and Other Accrued Liabilities, Current line stood at $151,931, with the gap between them representing accrued, non-trade obligations. The year-to-date statement of cash flows for the six months ended June 30, 2026 reports Net Cash Provided by (Used in) Operating Activities of -$4,701,378 and Net Cash Provided by (Used in) Financing Activities of $8,348,207, identifying financing, not operations, as the source of any cash entering the period.

- Management explanations Management’s discussion in the notes frames the operating cash outflow as a function of the same research-and-development accrual process used in preparing the statements, with the CEO acting as chief operating decision maker reviewing a consolidated loss-from-operations measure rather than segment data. The notes also flag that potentially dilutive securities — the subject of the cited note — were excluded from the diluted loss-per-share computation because their inclusion would have been anti-dilutive, a presentation choice rather than a capital-allocation decision.

- Analyst inference Because both the current and prior-year operating cash-flow lines for the six-month period are negative and the financing line for both periods is positive, the period’s liquidity is being sustained by external capital rather than internally generated cash. Trade payables remain a portion of total current liabilities to vendors and contract research organizations, consistent with a clinical-stage company that funds development work as services are rendered. - Counter-evidence No counter-evidence is disclosed in the filed statements; the notes describe only the reporting framework (two-class EPS method, anti-dilutive exclusion, CODM consolidation) and the foreign-currency translation policy, none of which offsets the operating-versus-financing split described above.

- Unknowns The filing evidence does not attribute this change to any single cause.. The filing does not break out investing-activity cash flow, beginning or ending cash balances, or the composition of accrued liabilities beyond the two reported lines, so any further split between accrued research-and-development costs, accrued compensation, and other accruals is not visible in this section’s evidence. The filing evidence contains no peer or industry comparison..

A reader comparing this six-month picture with peers such as those covered in Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction would need to look outside the filing for industry context.

Peer and historical context

Across both the three-month reporting period and the six-month year-to-date period, the bottom line moved in opposite directions on a year-over-year basis, even though every comparable figure sits in negative territory. Net Income (Loss) Attributable to Parent widened on a loss basis when the three-month reporting period is set against the prior-year comparative for the three-month reporting period, while the same line item narrowed on a loss basis when the six-month year-to-date period is compared with the prior-year comparative for the six-month year-to-date period.

In both readings the transition is from one loss to another loss, which limits how much weight can be placed on the directional shift alone. Operating Income (Loss) follows the same pattern: it widened on a loss basis for the three-month reporting period versus the prior-year comparative for the three-month reporting period, yet narrowed on a loss basis for the six-month year-to-date period versus the prior-year comparative for the six-month year-to-date period, again staying in loss territory across both windows. Earnings Per Share, Diluted moved higher year over year on a loss basis for both the three-month reporting period and the six-month year-to-date period, with a loss to loss transition in each window.

Operating cash flow, by contrast, deteriorated: Net Cash Provided by (Used in) Operating Activities for the six-month year-to-date period was more negative than the prior-year comparative for the six-month year-to-date period, reinforcing the picture that the headline net loss movement on the six-month window did not translate into a smaller cash burn from operations.

Scenario analysis

- The condensed consolidated results continue to show net loss attributable to parent for both the three-month period the three months ended June 30, 2026 and the six-month period the six months ended June 30, 2026, against negative prior-year comparables -$2,519,181 and -$4,704,147. - The authorized direction for net loss attributable to parent in the year-to-date window is an increase (i.e., a smaller loss) versus the prior-year loss, with the transition remaining loss-to-loss; for the three-month window the authorized direction is a decrease (a wider loss) versus the prior-year loss, also loss-to-loss. - Operating cash use remains the funding pattern implied by the authorized comparison for net cash used in operating activities (a larger use than the prior-year negative figure), while financing inflows are directed to rise versus the prior-year positive financing cash flow. - Capital raising described in Note 9 (Series C redeemable preferred stock) and the disclosures around the ATM Agreement and the registered direct / private placement transactions described in the share-capital narrative carry the base-case expectation that further equity-linked instruments will continue to fund operations while loss per share computations remain loss-to-loss on both basic and diluted bases per the cited reference Note 10.

- Six-month net loss attributable to parent narrows versus the prior-year loss -$4,704,147, consistent with the authorized increase direction for that period. - Operating cash burn moderates against the prior-year negative operating cash flow even as net financing inflows continue to expand versus the prior-year positive financing figure, leaving the loss-to-loss diluted EPS profile intact per Note 10. - The capital structure flexibility outlined in Note 9 (Series C mezzanine equity) and the ATM, registered direct and private placement vehicles described in the share-capital narrative remains available, supporting the going-concern narrative under the Authorized comparisons. - Cross-reference framing: comparable interim companies with narrow-loss or widening-loss profiles are examined in the related piece on Lizely Finance Earnings Analysis — Veru Inc. interim filing losses persist, with no peer benchmarking applied here.

- Three-month net loss attributable to parent widens against the prior-year loss -$2,519,181, matching the authorized decrease direction for the quarter while the diluted EPS transition stays loss-to-loss per Note 10. - Operating cash outflow increases against the prior-year negative figure, paired with a still-positive but lower financing inflow relative to the prior-year positive financing cash flow, narrowing the liquidity bridge to the next reporting window. - Dilution risk from the Series C preferred stock Note 9 and from the warrant packages referenced in the share-capital narrative (Series G, Series H and April Common Warrants plus the Pre-Funded Warrants disclosed in the same passage) compounds the share-count overhang, while basic and diluted loss per share continue to be reported on the same loss-per-share footing per Note 10. - The filing evidence does not attribute this change to any single cause.

Risks and what to watch

Reported facts: For the three-month reporting period under 10-Q for period-ended-2026-06-30 filed under accession 0001493152-26-038418 by Enveric Biosciences, Inc. (ENVB, CIK 0000890821), Net Income (Loss) Attributable to Parent was a loss of -$3,027,733 USD, compared with a loss of -$2,519,181 USD in the prior-year three-month period, a wider year-over-year loss. For the six-month year-to-date period, the figure was a loss of -$4,661,206 USD versus a loss of -$4,704,147 USD in the prior-year six-month period, a narrower year-over-year loss. Earnings Per Share, Diluted followed the same pattern: a loss-on-loss reading for both the quarter and the half year, with the half-year Diluted EPS moving in the higher direction and the quarter moving in the lower direction relative to the prior-year comparatives. Operating Income (Loss) tracked the same described direction at both the quarter and the half-year windows, also loss-to-loss. The required Part II items appear in the filing, including Item on Legal Proceedings, Item on Risk Factors, Item on Unregistered Sales of Equity Securities and Use of Proceeds, Item on Defaults Upon Senior Securities, Item on Other Information, Item on Controls and Procedures, and Item on Exhibits, corresponding to the cited reference points.

Management explanations: The narrative in the filing focuses on capital-raising mechanics rather than operating performance drivers. Management states that under the ATM Agreement, the Placement Agent will receive a percentage of the gross sales price of any shares sold, and that the number of shares, the per-share purchase price, and the aggregate gross proceeds that the Company will receive under the ATM Agreement are not predictable because the purchase price will fluctuate with the market price of Common Stock at the time of any election to sell. Management also describes a registered direct offering and a concurrent private placement with institutional investors, including the issuance of Series G and Series H warrants with the cited exercise prices and expiration terms, together with pre-funded warrants, and notes placement agent fees, accountable expenses, and legal and other offering-related fees that were similarly charged to additional paid-in capital.

Analyst inference: The combination of a narrower half-year loss with a wider quarterly loss implies that the second-quarter trajectory worsened sequentially within the six-month window, even though the cumulative six-month result improved versus the prior year. The prominence of equity-issuance mechanics in the narrative, with both an at-the-market facility and several warrant-linked offerings, points to equity-linked financing as the working-capital channel through which the cash flow from operating activities (negative in both periods) is being funded. For a comparable two-window revenue and net-income pattern at a peer, the Lizely filing note on REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing offers a directional contrast, while peers with persist losses and mixed year-over-year results are catalogued in the Lizely VERU interim analysis.

Counter-evidence: The filing does not include segment-level detail, balance-sheet exhibits, or a debt schedule beyond the discussed mezzanine Series C preferred reference in the cited note, and the specific numerical sensitivities of the net loss to operating expense line items are not narrated in the quoted material. The filing evidence does not attribute this change to any single cause.

Unknowns: Whether the warrant exercises, the placement agent fees, and the accretion from the pre-funded warrants will materially change the share count or the loss per share in the next period. The extent to which any legal proceedings disclosed under Item on Legal Proceedings will produce a contingent outflow is not described in the quoted evidence. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Metrics to watch next period: the reported net loss for the quarter and half-year, the cash flow from operating activities, the proceeds actually drawn under the ATM Agreement, the exercise notices for the Series G, Series H, Series I, and pre-funded warrants, and any updates to the Mezzanine equity Series C redeemable preferred stock referenced in the cited note and the potentially dilutive securities referenced in the cited note.